Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-PD-1 monoclonal antibody + platinum + pemetrexed
- Development stage
- Phase 2
- Lead developer
- Innovent Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination regimen is a standard-of-care chemo-immunotherapy for the first-line treatment of non-squamous non-small cell lung cancer (NSCLC). It comprises an anti-PD-1 monoclonal antibody (such as tislelizumab), a platinum-based chemotherapy agent (cisplatin or carboplatin), and pemetrexed (an antifolate antineoplastic agent). The regimen functions by simultaneously stimulating the immune system's anti-tumor response through PD-1 inhibition and inducing direct cytotoxic effects on cancer cells by interfering with DNA synthesis and repair. In the context of InxMed (Shanghai) Co., Ltd.'s clinical development, this triplet therapy serves as the active control arm in a Phase 3 trial evaluating the dual-oral combination of ifebemtinib (IN10018) and garsorasib (D-1553) for KRAS G12C-mutant non-squamous NSCLC.
- Other names
- anti-PD-1 monoclonal antibody + platinum + pemetrexedtislelizumab + platinum + pemetrexedstandard chemo-immunotherapy
02
Targets
DNADHFR (Dihydrofolate reductase)GART (GAR transformylase)PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)
Beyond the preview
Go deeper on anti-PD-1 monoclonal antibody + platinum + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-PD-1 monoclonal antibody + platinum + pemetrexed.